The Evolving Biology of Castration-Resistant Prostate Cancer: Review of Recommendations From the Prostate Cancer Clinical Trials Working Group 3

Praveen Ramakrishnan Geethakumari, Michael S. Cookson, William Kevin Kelly Do

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

In 2008, the Prostate Cancer Clinical Trials Working Group 2 (PCWG2) developed consensus guidelines for clinical trial design and conduct that redefined trial endpoints, with a dual-objective paradigm: to (1) controlling, relieving, or eliminating disease manifestations at the start of treatment; and (2) preventing or delaying further disease manifestations. Clinical and translational research in prostate cancer has expanded our current-day understanding of the mechanisms of its pathogenesis, as well as the different clinicopathologic and molecular subtypes of the disease, and has improved the therapeutic armamentarium for the management of metastatic castration-resistant prostate cancer (CRPC). These new advances led to the development of the updated PCWG3 guidelines in 2015. In this review, we analyze our evolving understanding of the biology of CRPC, acquired resistance mechanisms, and emerging therapeutic targets in light of the updated PCWG3 guidelines. We present a joint perspective from the medical oncology and urologic disciplines on the ongoing efforts to advance clinical trial performance in order to discover new therapies for this fatal disease.

Original languageEnglish (US)
JournalOncology (Williston Park, N.Y.)
Volume30
Issue number2
StatePublished - Feb 1 2016

Fingerprint

Castration
Prostatic Neoplasms
Clinical Trials
Guidelines
Translational Medical Research
Medical Oncology
Therapeutics
Joints

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{9fb25dbec2994b6695c143f93b1a8ff2,
title = "The Evolving Biology of Castration-Resistant Prostate Cancer: Review of Recommendations From the Prostate Cancer Clinical Trials Working Group 3",
abstract = "In 2008, the Prostate Cancer Clinical Trials Working Group 2 (PCWG2) developed consensus guidelines for clinical trial design and conduct that redefined trial endpoints, with a dual-objective paradigm: to (1) controlling, relieving, or eliminating disease manifestations at the start of treatment; and (2) preventing or delaying further disease manifestations. Clinical and translational research in prostate cancer has expanded our current-day understanding of the mechanisms of its pathogenesis, as well as the different clinicopathologic and molecular subtypes of the disease, and has improved the therapeutic armamentarium for the management of metastatic castration-resistant prostate cancer (CRPC). These new advances led to the development of the updated PCWG3 guidelines in 2015. In this review, we analyze our evolving understanding of the biology of CRPC, acquired resistance mechanisms, and emerging therapeutic targets in light of the updated PCWG3 guidelines. We present a joint perspective from the medical oncology and urologic disciplines on the ongoing efforts to advance clinical trial performance in order to discover new therapies for this fatal disease.",
author = "Geethakumari, {Praveen Ramakrishnan} and Cookson, {Michael S.} and Do, {William Kevin Kelly}",
year = "2016",
month = "2",
day = "1",
language = "English (US)",
volume = "30",
journal = "Oncology (Williston Park, N.Y.)",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "2",

}

TY - JOUR

T1 - The Evolving Biology of Castration-Resistant Prostate Cancer

T2 - Review of Recommendations From the Prostate Cancer Clinical Trials Working Group 3

AU - Geethakumari, Praveen Ramakrishnan

AU - Cookson, Michael S.

AU - Do, William Kevin Kelly

PY - 2016/2/1

Y1 - 2016/2/1

N2 - In 2008, the Prostate Cancer Clinical Trials Working Group 2 (PCWG2) developed consensus guidelines for clinical trial design and conduct that redefined trial endpoints, with a dual-objective paradigm: to (1) controlling, relieving, or eliminating disease manifestations at the start of treatment; and (2) preventing or delaying further disease manifestations. Clinical and translational research in prostate cancer has expanded our current-day understanding of the mechanisms of its pathogenesis, as well as the different clinicopathologic and molecular subtypes of the disease, and has improved the therapeutic armamentarium for the management of metastatic castration-resistant prostate cancer (CRPC). These new advances led to the development of the updated PCWG3 guidelines in 2015. In this review, we analyze our evolving understanding of the biology of CRPC, acquired resistance mechanisms, and emerging therapeutic targets in light of the updated PCWG3 guidelines. We present a joint perspective from the medical oncology and urologic disciplines on the ongoing efforts to advance clinical trial performance in order to discover new therapies for this fatal disease.

AB - In 2008, the Prostate Cancer Clinical Trials Working Group 2 (PCWG2) developed consensus guidelines for clinical trial design and conduct that redefined trial endpoints, with a dual-objective paradigm: to (1) controlling, relieving, or eliminating disease manifestations at the start of treatment; and (2) preventing or delaying further disease manifestations. Clinical and translational research in prostate cancer has expanded our current-day understanding of the mechanisms of its pathogenesis, as well as the different clinicopathologic and molecular subtypes of the disease, and has improved the therapeutic armamentarium for the management of metastatic castration-resistant prostate cancer (CRPC). These new advances led to the development of the updated PCWG3 guidelines in 2015. In this review, we analyze our evolving understanding of the biology of CRPC, acquired resistance mechanisms, and emerging therapeutic targets in light of the updated PCWG3 guidelines. We present a joint perspective from the medical oncology and urologic disciplines on the ongoing efforts to advance clinical trial performance in order to discover new therapies for this fatal disease.

UR - http://www.scopus.com/inward/record.url?scp=85044689669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044689669&partnerID=8YFLogxK

M3 - Article

C2 - 26888794

AN - SCOPUS:84959221030

VL - 30

JO - Oncology (Williston Park, N.Y.)

JF - Oncology (Williston Park, N.Y.)

SN - 0890-9091

IS - 2

ER -